Citigroup
CHRS icon

Citigroup’s Coherus Oncology CHRS Stock Holding History

Citigroup’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,600
Closed -$14K – 7657
2018
Q4 		$14K Hold
1,600
– – ﹤0.01% 7030
2018
Q3 		$26K Sell
1,600
-3,200
-67% -$56.7K ﹤0.01% 6955
2018
Q2 		$67K Buy
4,800
+1,200
+33% +$17.2K ﹤0.01% 6047
2018
Q1 		$40K Buy
3,600
+1,000
+38% +$10.9K ﹤0.01% 6326
2017
Q4 		$23K Buy
2,600
+800
+44% +$8.56K ﹤0.01% 6658
2017
Q3 		$24K Sell
1,800
-5,700
-76% -$75.4K ﹤0.01% 6376
2017
Q2 		$108K Buy
7,500
+2,500
+50% +$48.1K ﹤0.01% 5290
2017
Q1 		$106K Buy
+5,000
New +$123K ﹤0.01% 5165

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return